Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals is conducting a study titled ‘Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613’. The study aims to assess the long-term safety and effectiveness of the drug combination fianlimab and cemiplimab in patients with advanced melanoma who participated in a previous study. This research is significant as it seeks to provide insights into the long-term health outcomes of these patients.
The intervention being tested involves the drugs fianlimab and cemiplimab, which are designed to treat advanced melanoma. However, no study drug will be administered during this observational follow-up study.
The study is designed as an interventional, non-randomized, parallel assignment with no masking. Its primary purpose is to observe long-term health outcomes rather than administer treatment.
The study began on April 14, 2025, with its primary completion and estimated completion dates yet to be determined. The last update was submitted on July 15, 2025, indicating ongoing progress.
This update could influence Regeneron’s stock performance and investor sentiment by providing valuable data on the long-term efficacy of its melanoma treatments. In the competitive landscape of oncology, successful long-term outcomes could strengthen Regeneron’s position.
The study is ongoing, with further details available on the ClinicalTrials portal.